Basic Information
BOOSTRIX VACCINE
INJECTION
Regulatory Information
SIN11845P
March 9, 2002
Prescription Only
Therapeutic
INTRAMUSCULAR
August 10, 2023
June 3, 2025
XJ07AJ52
Company Information
GLAXOSMITHKLINE PTE LTD
GLAXOSMITHKLINE PTE LTD
Active Ingredients
Strength: 20 iu/0.5 ml
Strength: 2 iu/0.5 ml
Strength: 2.5 mcg/0.5 ml
Strength: 8 mcg/0.5 ml
Strength: 8 mcg/0.5 ml
Detailed Information
Contraindications
**Contraindications** _**Boostrix**_ should not be administered to subjects with known hypersensitivity to any component of the vaccine (see _Quantitative and Qualitative Composition_ and _List of Excipients_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_), or to subjects having shown signs of hypersensitivity after previous administration of diphtheria, tetanus or pertussis vaccines. _**Boostrix**_ is contraindicated if the subject has experienced an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis-containing vaccine. In these circumstances, pertussis vaccination should be discontinued and the vaccination course should be continued with diphtheria and tetanus vaccines. _**Boostrix**_ should not be administered to subjects who have experienced transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus (for convulsions or hypotonic-hyporesponsive episodes, see _Warnings and Precautions_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**Indications** _**Boostrix**_ is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals from the age of four years onwards (see _Posology_). The use of _**Boostrix**_ should be in accordance with official recommendations.